Standards; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
EED 226 is a potent, selective and orally bioavailable EED inhibitor, inducing robust and sustained tumor regression in specific models. Effective PRC2 inhibitorin the treatment of PRC2-dependant cancers.
您的位置：
